

Tilapia lake virus: Understanding the host immunity and challenges for vaccine development



Win Surachetpong (DVM, PhD, CertAqV, DTBVP)

Associate Professor

Department of Veterinary Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, THAILAND

Outline



Introduction: Tilapia Lake Virus (TiLV)



TiLV immunology



Vaccine development and challenges

Surachetpong_AFS_4 Aug 2021






Identification of a Novel RNA Virus Lethal to Tilapia


Marina Eyngor,^a Rachel Zamostiano,^b Japhette Esther Kembou Tsofack,^b Asaf Berkowitz,^a Hillel Bercovier,^c Simon Tinman,^d Menachem Lev,^e Avshalom Hurvitz,^f Marco Galeotti,^g Eran Bacharach,^b Avi Eldar^a

Department of Poultry and Fish Diseases, The Kimron Veterinary Institute, Bet Dagan, Israel^a; Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel^b; The Hebrew University-Hadassah Medical School, Jerusalem, Israel^c; Department of Animal Facility, Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel^d; Ein Gev Fisheries, Kibbutz Ein Gev, Israel^e; Dan Fish Farms, Kibbutz Dan, Upper Galilee, Israel^f; Department of Food Science, Section of Veterinary Pathology, University of Udine, Udine, Italy^g

Tilapia Lake Virus TiLV



Surachetpong_AFS_4 Aug 2021




Syncytial hepatitis of farmed tilapia, *Oreochromis niloticus* (L.): a case report

Journal of Fish Diseases 2014, 37, 583–589


H W Ferguson¹, R Kabuusu¹, S Beltran², E Reyes², J A Lince² and J del Pozo³

- 1 Marine Medicine Programme, School of Veterinary Medicine, St George's University, St George, Grenada
- 2 Produmar S.A., Guayaquil, Ecuador
- 3 Department of Pathology, Royal (Dick) School of Veterinary Medicine, University of Edinburgh, Edinburgh, Scotland, UK





Surachetpong_AFS_4 Aug 2021






Malaysia

- 50-80 g
- >80% mortality


Peru

- 300-400 g
- >40% mortality




Outbreaks of TiLV in Thailand (2015-16)

- From **32** outbreaks of high mortality → **22** are TiLV positive
- Bacteria, parasite and virus



Surachetpong et al., 2017

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 6, June 2017




Susceptible fish species for TiLV

- Wild tilapia
- Hybrid tilapia
(*O. niloticus* × *O. aureus* hybrids)
- Nile tilapia (*O. niloticus*)
- Red tilapia (*Oreochromis* spp.)
- Grey tilapia (*O. niloticus* × *O. aureus*)




Sarotherodon galilaeus



Tilapia zilli



Oreochromis aureus



Surachetpong_AFS_4 Aug 2021




Aquaculture 497 (2018) 463–468
Contents lists available at ScienceDirect
Aquaculture
journal homepage: www.elsevier.com/locate/aquaculture


Check for updates

Susceptibility of important warm water fish species to tilapia lake virus (TiLV) infection


Phitchaya Jaemwimol^a, Pattarasuda Rawiwan^{a,b}, Puntanat Tattiyapong^{a,b}, Patrawut Saengnuat^c, Attapon Kamlangdee^d, Win Surachetpong^{a,b,*}




Cyprinus carpio




Trichogaster pectoralis




Barbodes gonionotus




Lates calcarifer




Anabas testudineus



Clarias macrocephalus




Pangasianodon hypophthalmus




Chana striata

Surachetpong_AFS_4 Aug 2021

Most important warm water fish species are resistant to tilapia lake virus (TiLV) infection




TiLV
Susceptible ***Oreochromis* sp.**




TiLV
Susceptible ***Osphronemus goramy***


TiLV can infect ornamental African cichlids

- High mortality, virus detected in tissues




Days post-challenge	Cumulative mortality (%)
0	0
4	0
6	5
8	15
10	25
12	50
24	56.25







Tissue	Moribund fish (Copy number/µg RNA)	Surviving fish (Copy number/µg RNA)
Liver	~1.0 × 10 ⁸	~1.0 × 10 ⁶
Spleen	~1.0 × 10 ⁸	~1.0 × 10 ⁶
Anterior kidney	~1.0 × 10 ⁸	~1.0 × 10 ⁶



Yamkasem et al., 2021 (under review) Surachetpong_AFS_4 Aug 2021



Fish and Shellfish Immunology 116 (2021) 115–123

Contents lists available at ScienceDirect

Fish and Shellfish Immunology

journal homepage: www.elsevier.com/locate/fsi

Tilapia lake virus immunoglobulin G (TiLV IgG) antibody: Immunohistochemistry application reveals cellular tropism of TiLV infection

Chutchai Piewbang^{a,b,1}, Puntanat Tattiyapong^{c,1}, Somporn Techangamsuwan^{a,b,*}, Win Surachetpong^{c,***}


- TiLV localization in intestines, gills, liver, spleen, kidneys
- Endothelial cells and circulating lymphocytes

Surachetpong_AFS_4 Aug 2021


TiLVD is a **systemic** disease.... the virus is detected in most tissues.

Sample No.	Viral loads (copies/μg of total RNA)					
	Gills	Liver	Brain	Heart	Anterior kidney	Spleen
1	2.2×10^5	1.7×10^5	3.4×10^5	6.3×10^5	1.6×10^5	2.3×10^4
2	3.1×10^5	6.3×10^3	1.3×10^6	3.9×10^5	3.1×10^5	2.8×10^4

Tattiyapong et al., 2018 J Fish Dis.



Outline



Introduction: Tilapia Lake Virus (TiLV)



TiLV immunology



Vaccine development and challenges

Surachetpong_AFS_4 Aug 2021



Evidence of protective immunity against TiLV

- Once the initial wave of mortality ceased, no more outbreaks were recorded in the same pond. (Eyngor et al., 2014)
- The existence of fish that survived the TiLV-induced disease strongly suggests that **an effective immune response against this pathogen can be mounted**. This has important applications for future disease containment strategies. (Eyngor et al., 2014) such as vaccine development.

Surachetpong_AFS_4 Aug 2021




Repeat TiLV exposure do not cause disease and mortality in tilapia



Experiment	Group	Challenge method	No. of fish	Survival rate (%)	
				1 st challenge	2 nd challenge
1	Naïve	Intraperitoneal injection	20	25 (5/20)	100 (5/5)
			20	35 (7/20)	100 (7/7)
2		Cohabitation	15	40 (6/15)	100 (6/6)
			15	66 (10/15)	100 (10/10)
3	Previous TiLV exposure	Intraperitoneal injection	20	100 (20/20)	
20			100 (20/20)		
4		Cohabitation	15	100 (15/15)	
			15	100 (15/15)	

Surachetpong_AFS_4 Aug 2021

17


Tattiyapong et al., 2020 Fish & Shellfish Immunology





Antibody is the key immune response to control TiLV

- Rapid antibody response within 2 weeks
- Antibody persists for 4-5 months with anamnestic response.



Contents lists available at ScienceDirect

Aquaculture




journal homepage: www.elsevier.com/locate/aquaculture




Development and application of a recombinant protein-based indirect ELISA for detection of anti-tilapia lake virus IgM in sera from tilapia

- Segment 8 of TiLV

Huzi Hu^{a,c}, Weiwei Zeng^{a,*}, Yingying Wang^a, Qing Wang^a, Sven M. Bergmann^b, Jiyuan Yin^a, Yingying Li^a, Xiaoyu Chen^d, Caixia Gao^{a,c}, Defeng Zhang^a, Chun Liu^a, Yan REN^a, Cunbin Shi^a



Outline



Introduction: Tilapia Lake Virus (TiLV)



TiLV immunology




Vaccine development and challenges

Surachetpong_AFS_4 Aug 2021

23



VACCINES FOR FISH



**Where to focus next?
FIND THE BOTTLENECK**

Surachetpong_AFS_4 Aug 2021


24



Article

A high efficacy DNA vaccine against tilapia lake virus in Nile tilapia (*Oreochromis niloticus*)

Nai-tong Yu^{1*}, Wei-wei Zeng², Jian-hua Wang¹, Yu-liang Zhang¹, Xiu-chun Zhang¹, Zhi-xin Liu¹ • TiLV ORF10



Vaccinated tilapia	Cumulative mortality (death/total)	RPS%
pcDNA3.1-ORF10 (c)	13.33% (4/30)	85.72
pcDNA3.1-ORF10 (b)	20.00% (6/30)	78.57
pcDNA3.1-ORF10 (a)	36.67% (11/30)	60.71
pcDNA3.1	93.33% (28/30)	-



New grant will help develop vaccine delivery system for tilapia lake virus

By Shem Oirere
April 2, 2021



of 50 percent or more.

International Veterinary Vaccinology Network

Home / Funding / Fellowships programmes / Funded projects / Development of a nanoparticle Tilapia Lake Virus (TiLV) vaccine for tilapia aquaculture in India



Development of a nanoparticle Tilapia Lake Virus (TiLV) vaccine for tilapia aquaculture in India

Project summary

Aquaculture is the fastest growing food-production sector globally, with over 1 billion people relying on fish as their major protein source. Tilapia (*Oreochromis* sp.) is a major trade commodity for many low to middle-income countries (LMIC), with its production estimated to be around 6.4 million tons per annum (FAO, 2017). The hardiness of tilapia, its adaptability to various production systems and its rapid growth, makes it an excellent fish species for aquaculture. Intensification of tilapia farming has promoted severe disease outbreaks, however, resulting in high mortalities and economic hardship for tilapia farmers. Tilapia Lake Virus (TiLV), a highly virulent and contagious novel orthomyxo-like virus has recently been associated with disease outbreaks in tilapia aquaculture, resulting in massive mortalities in both wild and cultured tilapines. First reported in Israel in late 2009, TiLV-related disease outbreaks have now been reported across Asia, Africa, and North and South America. In Indian tilapia aquaculture, the virus is associated with mortality levels around 80-90%. Vaccination has proven a successful tool for controlling viral diseases in aquaculture, with most vaccines delivered by intraperitoneal (IP) injection. Many tilapia farmers will not vaccinate by injection since the fish have been moved onto the farm and would prefer fish to be vaccinated in the hatchery, it is difficult to inject small fish, however. Also TiLV tends to affect small fingerlings, some of which are too small to inject. Alternative vaccine delivery methods, such as oral or

Researchers involved in this project

- Dr Sreeja Lakshmi**
Kerala University of Fisheries and Ocean Studies, India
- Dr Preetham Elumalai**
Kerala University of Fisheries and Ocean Studies, India
- Dr Kim Thompson**
Moredun Research Institute, UK
- Dr David Smith**
Moredun Research Institute, UK

Take home message

- **Tilapia Lake virus** is threatening global tilapia aquaculture
- Fish survive TiLV infection develop **protective immunity** that prevents subsequent infection
- Different TiLV-prototype vaccines are under developed
- **Vaccine** and biosecurity will be important tools to reduce the disease

Surachetpong_AFS_4 Aug 2021

29



Thank you for
your attention

fvetwsp@ku.ac.th

